Ginkgo Bioworks and Soaring Eagle Acquisition today announced a business combination that values the engineered biology company at a $15 billion pre-money equity valuation and is expected to provide up to $2.5 billion of primary proceeds.
The deal includes a $775 million oversubscribed PIPE, with anchor investments from Baillie Gifford, Putnam Investments, and funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management). New investors including accounts advised by ARK Investment Management, ArrowMark Partners, Bain Capital Public Equity, Berkshire Partners, and Franklin Advisers also joined. Existing investors including Cascade Investment, Casdin Capital, General Atlantic, Senator Investment Group, funds and accounts advised by T. Rowe Price and Viking Global Investors are also participating.
Led by former MGM CEO Harry Sloan, Soaring Eagle raised $1.5 billion in a February IPO. Read more.
